- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07154615
- Juicio original
Evaluar la disfunción inmune en la sepsis
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
Descripción general del estudio
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Mrunmayi Tilak
- Número de teléfono: 612-624-9990
- Correo electrónico: mtilak@umn.edu
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- University of Minnesota
-
Contacto:
- Kristine Kancans
- Correo electrónico: kanca008@umn.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients with and without sepsis in the ICU, compared to healthy volunteers
Descripción
ICU With Sepsis Inclusion Criteria:
-
Age ≥ 18
-
Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"
-
Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:
- Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
- An alteration in mental status
- Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
- An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)
ICU Without Sepsis Inclusion Criteria:
- Age ≥ 18
- Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis
Healthy Volunteer Inclusion Criteria
- Age greater or equal to 18
- ASA status 1, 2 or 3
- May include patients who are receiving dialysis in an outpatient setting
Exclusion Criteria (all groups):
- Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
- Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
- Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
- Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
- Patients with active or a history of acute or chronic lymphocytic leukemia
- Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
- Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
- Participation in another investigational interventional drug study within the past 4 weeks
- Current pregnancy
- Current incarceration
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_CONTROL
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Voluntarios Saludables
|
No intervention is included in this study |
|
Pacientes de la UCI con sepsis
|
No intervention is included in this study |
|
Pacientes de la UCI sin sepsis
|
No intervention is included in this study |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
EliSpot - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
EliSpot - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
EliSpot - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
EliSpot - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
EliSpot - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
EliSpot - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Ex Vivo TNF Production - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Ex Vivo TNF Production - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Ex Vivo TNF Production - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Ex Vivo TNF Production - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Ex Vivo TNF Production - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Ex Vivo TNF Production - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Cytokines in Serum - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Cytokines in Serum - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Cytokines in Serum - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Cytokines in Serum - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Cytokines in Serum - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Cytokines in Serum - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Chemokines in Serum - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Chemokines in Serum - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Chemokines in Serum - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Chemokines in Serum - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Chemokines in Serum - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Chemokines in Serum - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Transcriptional Profiling - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Transcriptional Profiling - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Transcriptional Profiling - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Transcriptional Profiling - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Transcriptional Profiling - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Transcriptional Profiling - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
CBC - Day 1
Periodo de tiempo: Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
CBC - Day 4
Periodo de tiempo: Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
CBC - Day 7
Periodo de tiempo: Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
CBC - Day 14
Periodo de tiempo: Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
CBC - Day 21
Periodo de tiempo: Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
CBC - Day 28
Periodo de tiempo: Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Thomas Griffith, PhD, University of Minnesota
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- URO-2025-34202
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .